New therapeutic options for respiratory tract infections

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 178-186

  Bassetti, Matteo ^a   Righi, Elda ^a   Carnelutti, Alessia ^a  

^a Servicio de Urologia   (Italy)

Author keywords

Methicillin resistant Staphylococcus aureus; Multidrug resistance; New antimicrobials; Respiratory tract infections

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; CEFTAROLINE; CEFTOBIPROLE; CEFTOLOZANE PLUS TAZOBACTAM; DELAFLOXACIN; ERAVACYCLINE; TEDIZOLID; TELAVANCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; BACTERIAL INFECTIONS; MICROBIOLOGY; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84960108646     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000251     Document Type: Review

References (75)

1. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 2015;70:213-222.
2. Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and healthcare-associated pneumonia. Antimicrob Agents Chemother 2014;58:5262-5268.
3. Aliberti S, Cilloniz C, Chalmers JD, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013;68:997-999.
4. Kwa AL, Low JG, Lee E, et al. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 2007;58:99-104.
5. Lewis SS, Walker VJ, Lee MS, et al. Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals. Infect Control Hosp Epidemiol 2014;35:1452-1457.
6. Teshome BF, Lee GC, Reveles KR, et al. Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment. BMC Infect Dis 2015;15:380.
7. Koulenti D, Lisboa T, Brun-Buisson C, et al., EU-VAP/CAP Study Group. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009;37:2360-2368.
8. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014.
9. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869.
10. Brink AJ. Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? Curr Opin Crit Care 2012;18:451-459.
11. Ye ZK, Li C, Zhai SD. Guidelines for therapeutic drug monitoring of vancomycin: a systematic review. PLoS One 2014;9:e99044.
12. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillinresistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-629.
13. Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013;39:682-692.
14. Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 2015;41:776-795.
15. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011;52:1156-1163.
16. Castanheira M, Jones RN, Sader HS. Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. J Chemother 2014;26:202-210.
17. Pfaller MA, Flamm RK, Sader HS, Jones RN. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014;78:422-428.
18. Walkty A, Adam HJ, Laverdière M, et al., Canadian Antimicrobial Resistance Alliance (CARA). In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011;69:348-355.
19. File TM Jr, Low DE, Eckburg PB, et al., FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii19-iii32.
20. Low DE, File TM Jr, Eckburg PB, et al., FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii33-iii44.
21. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii53-iii59.
22. Lodise TP, Anzueto AR, Weber DJ, et al. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials. Antimicrob Agents Chemother 2015;59:1119-1126.
23. Canut A, Isla A, Rodríguez-Gascón A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skinstructure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 2015;45:399-405. PK/PD analysis supporting the use of high-dose ceftaroline in patients with suspected or confirmed MRSA infections.
24. Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents 2012;39:240-246.
25. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014;59:51-61. Efficacy and safety of ceftobiprole medocaril compared with ceftazidime plus blinezolid for the treatment of HAP.
26. Smith JR, Barber KE, Hallesy J, et al. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother 2015;59:5529-5534.
27. Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010;65:2396-2404.
28. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-886;
29. Erratum in: Drugs 2011;71:526.
30. Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008;52:2300-2304.
31. Rubinstein E, Lalani T, Corey GR, et al., ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52:31-40.
32. Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 2012;7:e41870.
33. Barriere SL. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol 2014;9:281-289.
34. Torres A, Rubinstein E, Corey GR, et al. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother 2014;69:1119-1126. Post-hoc analysis of data from the ATTAIN studies supporting the use of telavancin for the treatment of nosocomial pneumonia in patients with normal renal function.
35. Masterton R, Cornaglia G, Courvalin P, et al. The clinical positioning of telavancin in Europe. Int J Antimicrob Agents 2015;45:213-220.
36. Vasoo S, Cunningham SA, Cole NC, et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 2015;59:7842-7846. In-vitro antibacterial activity of avibactam in combination with different antimicrobials.
37. Keepers TR, Gomez M, Celeri C, et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against b-lactamaseproducing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2014;58:5297-5305. In-vitro activity of ceftazidime/avibactam against Enterobacteriacae and Pseudomonas aeruginosa.
38. Lahiri SD, Giacobbe RA, Johnstone MR, Alm RA. Activity ofavibactam against Enterobacter cloacae producing an extended-spectrum class C b-lactamase enzyme. J Antimicrob Chemother 2014;69:2942-2946.
39. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-b-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 2014;58:7007-7009.
40. Das S, Li J, Armstrong J, et al. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect 2015;3:e00172.
41. Tominaga N, Edeki T, Li J, et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother 2015;21:551-558.
42. Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebocontrolled studies. Clin Drug Invest 2015;35:307-317.
43. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidimeavibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015;59:6605-6607.
44. Winkler ML, Papp-Wallace KM, Hujer AM, et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2015;59:1020-1029.
45. Dallow J, Otterson LG, Huband MD, et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents 2014;44:552-556.
46. Housman ST, Crandon JL, Nichols WW, Nicolau DP. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 2014;58:1365-1371.
47. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51:826-830.
48. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014;43:533-539. In-vitro activity of ceftolozane/tazobactam against Enterobacteriacae and P. aeruginosa.
49. Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014;69:2713-2722.
50. Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 2012;67:2463-2469.
51. Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016;56:56-66. PK/PD analysis supporting the use of high-dose caftolozane/tazobactam for the treatment of pneumonia.
52. A prospective, randomized, double-blind, multicenter, phase 3 study to assess the safety and efficacy of intravenous ceftolozane/tazobactam compared with meropenem in adult patients with ventilated nosocomial pneumonia https://clinicaltrials.gov/ct2/show/NCT02070757.
53. Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother 2014;58:7198-7204.
54. Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015;59:864-871.
55. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann NY Acad Sci 2011;1241:48-70.
56. Flanagan S, Passarell J, Lu Q. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 2014;58:6462-6470.
57. Chen KH, Huang YT, Liao CH, et al. In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother 2015;59:6262-6265.
58. Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 2012;56:3420-3422.
59. Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis 2014;58(Suppl 1):S28-S34. PK/PD study supporting the potential role of tedizolid for the treatment of respiratory tract infections.
60. Tessier PR, Keel RA, Hagihara M, et al. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 2012;56:2342-2346.
61. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012;56:4713-4717.
62. Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 2012;67:2814-2820.
63. Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gramnegative organisms. Antimicrob Agents Chemother 2004;48:2771-2777.
64. Gunderson SM, Hayes RA, Quinn JP, Danziger LH. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2004;48:203-208.
65. Longcor J, Hopkins S, Wickler M, Laurence L. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). Presented at ID Week 2012; San Diego, California, USA. https://idsa.confex.com/idsa/.../Paper37764.html. [Accessed 12 January 2016]
66. Longcor J, Hopkins S, Wickler M, Laurence L. A phase 2 safety and efficacy study of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). Presented at ID Week 2012; San Diego, California, USA. https://idsa.confex.com/idsa/.../Paper37662.html. [Accessed 12 January 2016]
67. O'Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 2015;30:67-73.
68. Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother 2015;59:3469-3473.
69. Clark RB, Hunt DK, He M, et al. Fluorocyclines.2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem 2012;55:606-622.
70. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013;57:5548-5558.
71. Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015;59:1802-1805. In vitro activity of eravacycline against Enterobacteriacae and A. baumanii.
72. Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs 2014;23:1575-1584.
73. Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 2014;58:2113-2118. Phase I study supporting the potential role of eravacycline for the treatment of respiratory tract infections.
74. Grossman TH, Murphy TM, Slee AM, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother 2015;59:2567-2571.
75. Tetraphase announces top-line results from ignite2 phase 3 clinical trial of eravacycline in cUTI. https://ir.tphase.com/releasedetail.cfm?ReleaseID=930613. [Accessed 12 January 2016]